NocII

Product Name:NocII

Synonyms:Orphanin FQ 2

CAS No:188119-47-3

Purity:95%

Molar Mass:2081.4

Chemical Formula:C92H141N23O28S2

Storage:Store at -20 degrees Celsius

Sequence:FSEFMRQYLVLSMQSSQ

Application:

NocII is a synthetic peptide derived from the nociceptin/orphanin FQ precursor protein, designed to investigate the role of the nociceptin receptor (NOP) in pain modulation and other physiological processes. This peptide is commonly used in research to explore its effects on pain perception, stress response, and various central nervous system functions. NocII interacts with the NOP receptor, offering insights into the mechanisms of nociception and the development of potential therapeutic agents targeting pain, anxiety, and other neurological conditions. Its precise action and receptor specificity make it a valuable tool in neuropharmacological studies and drug development.

Current Research:

NocII, also known as Orphanin FQ2 (OFQ2), is a heptadecapeptide composed of 17 amino acids with the sequence H2N-Phe-Ser-Glu-Phe-Met-Arg-Gln-Tyr-Leu-Val-Leu-Ser-Met-Gln-Ser-Ser-Gln-OH. It is derived from the precursor protein prepronociceptin, situated immediately downstream of nociceptin (also known as Orphanin FQ), the endogenous ligand for the nociceptin/orphanin FQ peptide (NOP) receptor. NocII has been identified as an orphan neuropeptide with distinct physiological functions. Notably, it has been shown to stimulate locomotor activity in mice, indicating a potential role in modulating motor functions. The specific mechanisms through which NocII exerts its effects are not fully elucidated, and its receptor interactions remain a subject of ongoing research. The discovery of NocII expands the understanding of the complex regulatory systems involving neuropeptides derived from prepronociceptin. Its functional relationship with nociceptin suggests a coordinated role in physiological processes, including pain modulation and motor activity. In summary, NocII is a neuropeptide originating from the prepronociceptin precursor, with emerging evidence supporting its involvement in stimulating locomotion in animal models. Further research is necessary to delineate its receptor targets and broader physiological implications.

Reference:

Florin, S., Leblond, F., Suaudeau, C., Meunier, J. C., & Costentin, J. (1999). Comparison of behavioural effects of NocII or NocIII, two related pronociceptin-derived peptides. Life sciences, 65(25), 2727-2733.